基于锡 (II) 催化的不对称醛醇反应(手性路易斯酸控制合成(CLAC 合成)),已经开发了鞘氨醇 B 和 F 及其立体异构体的明确合成路线。使用催化量的手性源进行有效的对映选择性合成以及该策略在合成鞘氨醇家族中的有效性已被成功证明。使用合成的鞘氨醇 B 的立体异构体,揭示了其立体化学与其 SPT 抑制活性的相关性。
Process for the synthesis of prostaglandin derivatives
申请人:Technopharma S.A.
公开号:EP1721894A1
公开(公告)日:2006-11-15
An alternative method for the synthesis of prostaglandin F analogues, in particular, analogues of PGF2α and specifically for the synthesis of latano-prost, wherein the transformation of the lactone intermediate (5)
into the corresponding lactol (7)
is carried out by treating the lactone intermediate (5) with a silane, preferably polymethylhydrosiloxane (PMHS), in the presence of a titanocene - and preferably titanocene fluoride.
The method enables considerable production economies with respect to the conventional reduction of lactone with diisobutylaluminum hydride (DIBAL-H).
Diaryl Ether Formation Merging Photoredox and Nickel Catalysis
作者:Le Liu、Cristina Nevado
DOI:10.1021/acs.organomet.1c00018
日期:2021.7.26
Photoredox and Ni catalysis are combined to produce diaryl ethers under mild conditions. A broad range of aryl halides and phenol derivatives are cross-coupled in the presence of a readily available organic photocatalyst and NiBr2(dtbpy). Symmetrical diaryl ethers have also been directly obtained from aryl bromides in the presence of water. Mechanistic investigations support the involvement of Ni(0)
[EN] METALLOENZYME INHIBITOR COMPOUNDS AS FUNGICIDES<br/>[FR] COMPOSÉS INHIBITEURS DE MÉTALLO-ENZYMES EN TANT QUE FONGICIDES
申请人:DOW AGROSCIENCES LLC
公开号:WO2015160665A1
公开(公告)日:2015-10-22
The instant invention describes compounds of Formula I having metalloenzyme modulating activity, and methods of treating diseases disorders or symptoms thereof mediated by such metalloenzymes.
Improved Process for the Production of Prostaglandins and Prostaglandin Analogs
申请人:SANDOZ AG
公开号:EP2143712A1
公开(公告)日:2010-01-13
The present invention relates to an improved process for the production of prostaglandins and prostaglandin analogs. In particular, this invention relates to the production of prostaglandins of the PGF2α-series, including latanoprost, travoprost, and bimatoprost, which are active pharmaceutical ingredients used for the reduction of elevated intraocular pressure in patients with glaucoma and ocular hypertension.